Immunotherapy for lung adenocarcinoma patients with bone metastases: who really needs it
This study provides convincing evidence that immunotherapy provides a significant survival advantage for LABM. Secondly, the clinical tools constructed in this study can help clinicians identify the optimal population to benefit from immunotherapy in LABM, thus enabling precise treatment and avoiding the waste of medical resources and over-treatment of patients.
Authors
- Lujian Zhu (ORCID: https://orcid.org/0009-0002-4996-1446)
- Yuexin Tong
- Zhangheng Huang (ORCID: https://orcid.org/0000-0002-6885-098X)
- Binbin Yang (ORCID: https://orcid.org/0000-0001-6943-9925)
- Kai Chen (ORCID: https://orcid.org/0000-0002-7233-5892)
- Peiling Dai
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-13
- DOI
- https://doi.org/10.3389/fimmu.2024.1457916
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00